Biography • Patents

Thomas H Beck is the head of Sidley's New York IP group, and focuses on complex chemical and pharmaceutical litigation matters. In February 2012 Mr Beck won a two week jury trial for Sunovion in Hatch-Waxman litigation against Mylan concerning the asthma medication Xopenex (levalbuterol), winning lost profits, reasonable royalty and a finding of willful infringement. The National Law Journal listed that verdict in the top 100 jury verdicts for 2012, and it was also in the top 20 IP jury awards for 2012. He is lead counsel for Noven Pharmaceuticals in Hatch-Waxman litigation against Watson concerning the Daytrana transdermal patch treatment for ADHD, and he is also lead counsel for ConvaTec in litigation brought by KCI and Wake Forest University concerning negative pressure wound therapy. He was recently lead IP counsel for LSI in litigation against Xilinx involving numerous patents relating to programmable field gate arrays and related circuits. He was lead counsel in several successful multi-million dollar mediation and arbitration efforts, including Marvell v Agere which involved 802.11 WiFi networks.

Mr Beck was lead or co-lead counsel for Eli Lilly and Company, Schering-Plough, GlaxoSmithKline, Bristol-Myers Squibb, Sanofi-Aventis and others, concerning matters such as the ADHD drug atomoxetine, the anticholesterol drug ezetimibe, the antidiabetic drug rosiglitazone maleate, the anti-cancer drug paclitaxel and the platelet inhibitor agent clopidogrel bisulfate. He was lead counsel for Bristol in the Bristol v RPR case, in which RPR's patent claims were found unenforceable, and the SDNY awarded Bristol's attorney fees for the six year battle.

Mr Beck received his JD from Harvard Law School in 1979 and his BS (with honors) from North Dakota State University in 1975.

Biography • Life Sciences - IP

Thomas H Beck is the head of the New York IP group, and focuses on complex chemical and pharmaceutical litigation matters. Mr Beck recently won a 2 week jury trial for Sunovion in Hatch-Waxman litigation against Mylan concerning the asthma medication Xopenex (levalbuterol), winning lost profits, reasonable royalty and a finding of willful infringement. He is currently lead counsel for Sunovion against Watson in a second litigation concerning Xopenex in a multiple dose pump formulation. Mr Beck is also lead counsel for Noven Pharmaceuticals in Hatch-Waxman litigation against Watson concerning the Daytrana transdermal patch treatment for ADHD, and he is also lead counsel for ConvaTec in litigation brought by KCI and Wake Forest University concerning negative pressure wound therapy. He is lead IP counsel for LSI in several litigations concerning certain SAS switches. Mr Beck has also been lead counsel in several successful multi-million dollar mediation and arbitration efforts, including Marvell v Agere which involved 802.11 WiFi networks.

Mr Beck was lead or co-lead counsel for cases involving the ADHD drug atomoxetine, the anticholesterol drug ezetimibe, the antidiabetic drug rosiglitazone maleate, the anti-cancer drug paclitaxel and the platelet inhibitor agent clopidogrel bisulfate.

Mr Beck received his JD from Harvard Law School in 1979 and his BS (with honors) from North Dakota State University in 1975. Admissions include US Court of Appeals, Federal Circuit; US District Court, ED of New York; US District Court, SD of New York; New York.